IOVA - Iovance Biotherapeutics, Inc.
NEXT EARNINGS:
May 7, 2026
EPS Est: $-0.14
|
Rev Est: $85.0M
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$2.00
DETAILS
HIGH:
$2.00
LOW:
$2.00
MEDIAN:
$2.00
CONSENSUS:
$2.00
DOWNSIDE:
47.09%
Market Cap:
1.25B
Volume:
69,367,038
Avg Volume:
11,142,283
52 Week Range:
1.64-5.88
Sector:
Healthcare
Industry:
Biotechnology
Beta:
0.78
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
838
IPO Date:
2010-10-15
EPS (TTM):
-1.09
P/E Ratio:
-2.50
Revenue (TTM):
263.50M
Total Assets:
913.17M
Total Debt:
48.44M
Cash & Equiv:
163.08M
Rev Growth (5Y):
13699.0%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
N/A
Debt/Equity:
0.07
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-02-24 | $-0.18 | $-0.22 | +18.2% | $86.7M | $90.6M | -4.3% |
| 2025-11-06 | $-0.25 | $-0.29 | +13.8% | $67.5M | $82.2M | -17.9% |
| 2025-08-07 | $-0.33 | $-0.29 | -13.8% | $60.0M | $78.3M | -23.5% |
| 2025-05-08 | $-0.36 | $-0.25 | -44.0% | $49.3M | $82.4M | -40.1% |
| 2025-02-27 | $-0.26 | $-0.26 | 0.0% | $73.7M | $72.2M | +2.1% |
| 2024-11-07 | $-0.28 | $-0.31 | +9.7% | $58.6M | $71.6M | -18.2% |
| 2024-08-08 | $-0.34 | $-0.37 | +8.1% | $31.1M | $24.6M | +26.5% |
| 2024-05-09 | $-0.42 | $-0.45 | +6.7% | $715000 | $2.1M | -65.5% |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 263.50M | 164.07M | 1.19M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (390.98M) | (372.18M) | (444.04M) | (395.89M) | (342.25M) | (259.58M) | (197.56M) | (123.58M) | (92.06M) | (52.89M) | (27.66M) | (12.04M) |
| EPS | -1.09 | -1.28 | -1.89 | -2.49 | -2.23 | -1.88 | -1.50 | -1.27 | -1.41 | -0.96 | -0.62 | -0.48 |
| Total Assets | 913.17M | 910.43M | 780.35M | 663.98M | 777.33M | 768.46M | 344.65M | 480.82M | 155.37M | 171.89M | 105.65M | 46.51M |
| Total Debt | 48.44M | 58.26M | 75.86M | 85.45M | 71.53M | 51.66M | 11.50M | 0 | 0 | 0 | 0 | 0 |
| Cash & Equivalents | 163.08M | 115.69M | 114.89M | 231.73M | 78.23M | 67.33M | 13.97M | 82.15M | 145.37M | 166.47M | 103.70M | 44.91M |
| Operating Cash Flow | (302.41M) | (352.98M) | (361.82M) | (292.76M) | (227.94M) | (205.13M) | (158.89M) | (101.25M) | (78.71M) | (32.67M) | (18.38M) | (8.63M) |
| Free Cash Flow | (336.24M) | (364.05M) | (384.11M) | (313.18M) | (265.51M) | (251.93M) | (165.81M) | (102.45M) | (79.74M) | (34.19M) | (19.52M) | (10.23M) |
| FCF per Share | -0.94 | -1.26 | -1.63 | -1.97 | -1.73 | -1.82 | -1.33 | -1.05 | -1.22 | -0.62 | -0.44 | -0.41 |
| Book Value | 698.58M | 710.40M | 584.61M | 499.64M | 621.66M | 656.50M | 298.97M | 466.19M | 145.48M | 166.92M | 104.02M | 44.85M |
| Cash & ST Investments | 296.98M | 323.78M | 279.87M | 471.85M | 504.41M | 629.44M | 307.08M | 468.52M | 145.37M | 166.47M | 103.70M | 44.91M |
| ROC Equity | -0.56 | -0.52 | -0.76 | -0.79 | -0.55 | -0.40 | -0.66 | -0.27 | -0.63 | -0.32 | -0.27 | -0.27 |